Error: Could not add to watchlist. X

Avanir Pharmaceuticals Inc

+ Watchlist
AVNR:US
Acquired
AVNR:US was acquired by 4578:JP
USD
Volume
0
Current P/E Ratio (TTM)
-
Earnings per Share (USD) (TTM)
-0.31
Market Cap (USD)
-
Shares Outstanding (m)
193.759
Price/Sales (TTM)
-
Dividend Indicated Gross Yield
-
Sector
Health Care
Industry
Biotech & Pharma
Sub-Industry
Specialty Pharma

Related Videos

There are currently no related videos for this ticker. Please check back later.
Profile
Avanir Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases. The Company develops treatments for pseudobulbar affect, diabetic peripheral neuropathic pain, and other conditions. AVANIR out-licensed its moniclonal antibodies, and produces an over-the-counter treatment for cold sores.
ADDRESS
101 Enterprise
Suite 300
Aliso Viejo, CA 92656
United States
PHONE
1-949-389-6700
  • Keith A Katkin
    President/CEO
  • Rohan Palekar
    Senior VP/Chief Commercial Ofcr
  • Gregory J Flesher "Greg"
    Senior VP:Corporate Dev/Chief Bus Ofcr
  • Joao Siffert
    Senior VP:R&D/Chief Scientific Ofcr
  • Christine G Ocampo
    VP:Finance/Chief Acctg Officer
Show More